Digesting the Doughnut Hole

Overview

Journal J Health Econ

Specialty Health Services

Date 2013 Dec 7

PMID 24308883

Citations 12

Authors

Geoffrey F Joyce

Julie Zissimopoulos

Dana P Goldman

Affiliations

Soon will be listed here.

Abstract

Despite its success, Medicare Part D has been widely criticized for the gap in coverage, the so-called "doughnut hole". We compare the use of prescription drugs among beneficiaries subject to the coverage gap with usage among beneficiaries who are not exposed to it. We find that the coverage gap does, indeed, disrupt the use of prescription drugs among seniors with diabetes. But the declines in usage are modest and concentrated among higher cost, brand-name medications. Demand for high cost medications such as antipsychotics, antiasthmatics, and drugs of the central nervous system decline by 8-18% in the coverage gap, while use of lower cost medications with high generic penetration such as beta blockers, ACE inhibitors and antidepressants decline by 3-5% after reaching the gap. More importantly, lower adherence to medications is not associated with increases in medical service use.

Citing Articles

Do High-Deductible Health Plans Incentivize Changing the Timing of Substance Use Disorder Treatment?.

Hollander M, Kennedy-Hendricks A, Schilling C, Meiselbach M, Stuart E, Huskamp H Med Care Res Rev. 2023; 80(5):530-539.

PMID: 37345300 PMC: 10961140. DOI: 10.1177/10775587231180667.

Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs.

Liu J, Zhang Y, Kaplan C Health Econ. 2022; 32(3):639-653.

PMID: 36399360 PMC: 9898097. DOI: 10.1002/hec.4637.

Financial hardship from purchasing prescription drugs among older adults in the United States before, during, and after the Medicare Part D "Donut Hole": Findings from 1998, 2001, 2015, and 2021.

Olson A, Schommer J, Mott D, Adekunle O, Brown L J Manag Care Spec Pharm. 2022; 28(5):508-517.

PMID: 35471065 PMC: 10373028. DOI: 10.18553/jmcp.2022.28.5.508.

Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure.

Gokhale M, Dusetzina S, Pate V, Chun D, Buse J, Sturmer T Diabetes Care. 2020; 43(9):2121-2127.

PMID: 32641378 PMC: 7440898. DOI: 10.2337/dc19-1880.

Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D.

Einav L, Finkelstein A, Polyakova M Am Econ J Econ Policy. 2018; 10(3):122-153.

PMID: 30233766 PMC: 6141206. DOI: 10.1257/pol.20160355.

References

Yin W, Basu A, Zhang J, Rabbani A, Meltzer D, Alexander G . The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008; 148(3):169-77. DOI: 10.7326/0003-4819-148-3-200802050-00200. View

Zhang Y, Donohue J, Newhouse J, Lave J . The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009; 28(2):w317-25. PMC: 2859617. DOI: 10.1377/hlthaff.28.2.w317. View

Motheral B, Fairman K . Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001; 39(12):1293-304. DOI: 10.1097/00005650-200112000-00005. View

Hsu J, Price M, Huang J, Brand R, Fung V, Hui R . Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006; 354(22):2349-59. DOI: 10.1056/NEJMsa054436. View

Fairman K, Motheral B, Henderson R . Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2004; 25(12):3147-61. DOI: 10.1016/s0149-2918(03)90099-3. View

Johnson R, GOODMAN M, Hornbrook M, Eldredge M . The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997; 35(11):1119-31. DOI: 10.1097/00005650-199711000-00004. View

Hsu J, Fung V, Price M, Huang J, Brand R, Hui R . Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008; 299(16):1929-36. DOI: 10.1001/jama.299.16.1929. View

Tseng C, Brook R, Keeler E, Steers W, Mangione C . Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004; 292(8):952-60. DOI: 10.1001/jama.292.8.952. View

Ketcham J, Simon K . Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manag Care. 2008; 14(11 Suppl):SP14-22. View

10.

McWilliams J, Zaslavsky A, Huskamp H . Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA. 2011; 306(4):402-9. DOI: 10.1001/jama.2011.1026. View

11.

Joyce G, Goldman D, Vogt W, Sun E, Jena A . Medicare part D after 2 years. Am J Manag Care. 2009; 15(8):536-44. PMC: 3767434. View

12.

Zhang Y, Donohue J, Lave J, ODonnell G, Newhouse J . The effect of Medicare Part D on drug and medical spending. N Engl J Med. 2009; 361(1):52-61. PMC: 2859614. DOI: 10.1056/NEJMsa0807998. View

13.

Polinski J, Shrank W, Huskamp H, Glynn R, Liberman J, Schneeweiss S . Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Med. 2011; 8(8):e1001075. PMC: 3156689. DOI: 10.1371/journal.pmed.1001075. View

14.

Lichtenberg F, Sun S . The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007; 26(6):1735-44. DOI: 10.1377/hlthaff.26.6.1735. View